In this study, we retrospectively analyzed the outcomes of 44 patients with advanced BRAF-mutant NSCLC who were treated with a mix of immune checkpoint inhibitors and chemotherapy. This evidence concerns the gene BRAF and non-small cell lung carcinoma.